ovarian cancer most lethal all gynaecolog cancer among women serum ca125 onli biomark use routin need further complementari biomark both term sensit specif glycosyl chang ovarian cancer serum glycoprotein includ decreas galactosyl igg increas sialyl lewi sle haptoglobin chain 1acid glycoprotein 1antichymotrypsin these chang also present chronic inflamm malign melanoma where low level inflammatori process acute phase protein carri increas amount sle have increas halflif sialyl acut phase protein also decreas apoptosi favour surviv cancer cell cancer cell produc inflammatori cytokin which influenc glycosyl process liver parenchym cell altere glycosyl acut phase protein transferrin play import role iron homeostasi glycosyl transferrin it glycan have antiapoptot properti mani transferrin receptor carcinoma could play role develop anaemia decreas galactosyl sialyl igg increas cytotox natur killer cell complement activ via mannosebind lectin mbl altere glycosyl acut phase protein igg suggest cancer regul certain pathway favour cancer cell surviv

Radka Saldova

Mark R. Wormald

Raymond A. Dwek

Pauline M. Rudd

Glycosylation Changes on Serum Glycoproteins in Ovarian Cancer May Contribute to Disease Pathogenesis

once dismiss just ice cake sugar molecul emerg vital compon life intric machineri our understand function within context protein lipid which attach has matur rapid far reach clinic implic becom understoodrec advanc highthroughput glycom techniqu glyco biomark profil glycobioinformat develop increas sophist glycoarray combin our increas understand molecular detail glycosyl have facilit linkag between aberr glycosyl human diseas highlight possibl use glycobiomark potenti determin diseas it progressionth focus review give insight biolog signific glycomodif highlight some specif exampl glycobiomark relat autoimmun particular rheumatoid arthriti explor excit possibl exploit diagnost prognost strategi

Azita Alavi

John S. Axford

Glyco-biomarkers: Potential Determinants of Cellular Physiology and Pathology

Marion Boland

Editorial

prostat cancer lead caus cancer death among men current avail screen test measur prostatespecif antigen psa detect prostat cancer howev test produc fals posit valu often lead negat biopsi therefor more reliabl diagnost tool need glycan serum particular interest around half all protein glycosyl studi nlink glycan were enzymat releas pngase from prostat epitheli cell line prns express wild type mutant androgen receptor small set human serum sampl releas glycan were purifi partit neutral acid compon solid phase extract spe use graphit carbon cartridg the spe fraction were analyz matrixassist laser desorpt ioniz fourier transform ion cyclotron reson mass spectrometri maldi fticr signific chang some highmannos fucosyl biantennari complex nlink glycan were observ serum prostat cancer patient

Maria Lorna A. de Leoz

Hyun Joo An

Scott Kronewitter

Jaehan Kim

Sean Beecroft

Ruth Vinall

Suzanne Miyamoto

Ralph de Vere White

Kit S. Lam

Carlito Lebrilla

Glycomic Approach for Potential Biomarkers on Prostate Cancer: Profiling of N-Linked Glycans in Human Sera and pRNS Cell Lines

spontan mutat multipl oncogen tumor suppressor gene colon epitheli cell it progeni may caus prolifer out control creat benign colon neoplasm colon polyp addit mutat involv gene respons cell adhes movement aberr epitheli cell may becom malign colon cancer invad surround remot tissu creat secondari tumor call metastasesincid colorect cancer dramat increas 5065 year age europ 2006 colorect cancer consist 129 all cancer caus 207 400 deathsto laboratori detect monitor colon cancer use tumor marker tumor marker substanc produc bodi respons cancer cancer tissu itself glycoconjug marker colon cancer includ aberr mucin cover surfac colon epitheli cell cadherin selectin like adhes molecul mediat cellcel adhes integrin integr membran proteoglycan respons adhes colon epitheli cell extracellular matrix glycoconjug compon ecm well lysosom membran glycoprotein exoglycosidasesdetect colon cancer earli non malign stage crucial it prevent erad colon cancer effect accumul mani somat mutat oncogen supressor mismatch repair gene mani gene respons posttransl modif protein multidirect approach should appli it detect glycobiolog approach diagnosi treatment colorect cancer should direct detect chang glycosyl accompani everi step colon cancer progress correl between chang glycosyl tumor progress

Sławomir Dariusz Szajda

Anna Jankowska

Krzysztof Zwierz

Carbohydrate Markers in Colon Carcinoma

inflammatori diseas accompani numer chang site inflamm well mani system physiolog biochem chang past two decad more more attent be paid chang glycosyl review describ some chang found main serum protein α1acid glycoprotein immunoglobulin immunoglobulin transferrin haptoglobin α2macroglobulin creactiv protein other molecular background physiolog import most chang yet discov evid glycosyl play import role inflammatori respons mayb greatest valu chang current lay potenti diagnost prognost usag either combin current diagnost marker own howev determin glycan structur still technic too complex most clinic laboratori further effort have made develop simpl analyt tool studi chang glycosyl

Olga Gornik

Gordan Lauc

Glycosylation of Serum Proteins in Inflammatory Diseases

chang nlink glycosyl known occur dure develop various diseas for exampl increas branch oligosaccharid has been associ cancer metastasi has been correl tumor progress human cancer breast colon melanoma increas core fucosyl have also been associ develop hepatocellular carcinoma hcc recent chang both total serum glycom glycosyl specif igg molecul have been observ peopl liver fibrosi cirrhosi the mechan which chang glycosyl observ use biomark diseas discuss

Anand Mehta

Timothy M. Block

Fucosylated Glycoproteins as Markers of Liver Disease

the lack specif sensit tumour marker earli detect cancer drive search new approach could identifi biomark marker need alert clinician earli stage tumourogenesi befor cancer has metastas when therapeut drug more effect most tumour marker current use clinic serum glycoprotein frequent high glycosyl mucin typic diseas marker protein glycan moieti correspond glycoprotein mucin the increas knowledg role glycan cancer suggest further studi may assist both determin role everi step tumour progress design new therapeut diagnos approach detect alter glycan serum tumour glycoprotein could way achiev specif tumour detect review focus glycan chang two serum glycoprotein prostat specif antigen current use tumour marker prostat cancer human pancreat ribonucleas pancreat adenocarcinoma the detect glycan chang associ subset glycoform serum glycoprotein specif tumour situat could basi develop more specif biomark

Rosa Peracaula

Sílvia Barrabés

Ariadna Sarrats

Rafael de Llorens

Altered Glycosylation in Tumours Focused to Cancer Diagnosis

About this journal

Disease Markers publishes papers related to the identification of disease markers, the elucidation of their role and mechanism, as well as their application in the prognosis, diagnosis and treatment of diseases.

Journal profile

Meet the editorial board

Disease Markers maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors expert and up-to-date in the field of study.

Editor spotlight

Submit to Special Issue

We currently have a number of Special Issues open for submission. Special Issues highlight emerging areas of research within a field, or provide a venue for a deeper investigation into an existing research area.

Special Issues

Author guidelines

Editorial board

Databases and indexing

Disease Markers

This Issue is now open for submissions.
Papers are published upon acceptance, regardless of the Special Issue publication date.

Call for papers

	Pauline M. Rudd